B. Riley upgraded shares of InfuSystem (NYSE:INFU - Free Report) to a strong-buy rating in a report published on Wednesday morning, Zacks.com reports.
Separately, StockNews.com upgraded InfuSystem from a buy rating to a strong-buy rating in a research note on Friday, September 20th.
Read Our Latest Stock Analysis on INFU
InfuSystem Trading Up 2.9 %
Shares of INFU traded up $0.19 during trading hours on Wednesday, hitting $6.75. The company had a trading volume of 49,509 shares, compared to its average volume of 56,383. The firm has a market cap of $143.74 million, a price-to-earnings ratio of -675,000.00 and a beta of 1.46. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64. InfuSystem has a one year low of $5.74 and a one year high of $10.99.
InfuSystem (NYSE:INFU - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). InfuSystem had a return on equity of 0.70% and a net margin of 0.28%. The business had revenue of $33.70 million for the quarter.
Institutional Trading of InfuSystem
A number of hedge funds have recently modified their holdings of the stock. Rhumbline Advisers raised its holdings in shares of InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company's stock valued at $121,000 after acquiring an additional 2,145 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of InfuSystem during the second quarter valued at approximately $131,000. Oppenheimer Asset Management Inc. raised its holdings in shares of InfuSystem by 52.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company's stock valued at $178,000 after acquiring an additional 8,917 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in shares of InfuSystem during the second quarter valued at approximately $208,000. Finally, ARS Investment Partners LLC raised its holdings in shares of InfuSystem by 11.4% during the second quarter. ARS Investment Partners LLC now owns 33,510 shares of the company's stock valued at $229,000 after acquiring an additional 3,422 shares during the last quarter. Hedge funds and other institutional investors own 71.13% of the company's stock.
InfuSystem Company Profile
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
See Also
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
